These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32299331)

  • 1. Scientific evidence supporting recommendations on the use of the 9-valent HPV vaccine in a 2-dose vaccine schedule in Australia.
    Wnukowski-Mtonga P; Jayasinghe S; Chiu C; Macartney K; Brotherton J; Donovan B; Hall M; Smith DW; Peterson K; Campbell-Lloyd S; Selvey C; Giles M; Kaldor J; Marshall H;
    Commun Dis Intell (2018); 2020 Apr; 44():. PubMed ID: 32299331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women.
    Iversen OE; Miranda MJ; Ulied A; Soerdal T; Lazarus E; Chokephaibulkit K; Block SL; Skrivanek A; Nur Azurah AG; Fong SM; Dvorak V; Kim KH; Cestero RM; Berkovitch M; Ceyhan M; Ellison MC; Ritter MA; Yuan SS; DiNubile MJ; Saah AJ; Luxembourg A
    JAMA; 2016 Dec; 316(22):2411-2421. PubMed ID: 27893068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.
    Petrosky E; Bocchini JA; Hariri S; Chesson H; Curtis CR; Saraiya M; Unger ER; Markowitz LE;
    MMWR Morb Mortal Wkly Rep; 2015 Mar; 64(11):300-4. PubMed ID: 25811679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.
    Vesikari T; Brodszki N; van Damme P; Diez-Domingo J; Icardi G; Petersen LK; Tran C; Thomas S; Luxembourg A; Baudin M
    Pediatr Infect Dis J; 2015 Sep; 34(9):992-8. PubMed ID: 26090572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
    Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
    Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine.
    Zhang Z; Zhang J; Xia N; Zhao Q
    Hum Vaccin Immunother; 2017 Oct; 13(10):2280-2291. PubMed ID: 28699820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine.
    Guevara A; Cabello R; Woelber L; Moreira ED; Joura E; Reich O; Shields C; Ellison MC; Joshi A; Luxembourg A
    Vaccine; 2017 Sep; 35(37):5050-5057. PubMed ID: 28789851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.
    Gilca V; Sauvageau C; Panicker G; De Serres G; Ouakki M; Unger ER
    Vaccine; 2018 Nov; 36(46):7017-7024. PubMed ID: 30314913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up.
    Olsson SE; Restrepo JA; Reina JC; Pitisuttithum P; Ulied A; Varman M; Van Damme P; Moreira ED; Ferris D; Block S; Bautista O; Gallagher N; McCauley J; Luxembourg A
    Papillomavirus Res; 2020 Dec; 10():100203. PubMed ID: 32659510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men.
    Van Damme P; Meijer CJLM; Kieninger D; Schuyleman A; Thomas S; Luxembourg A; Baudin M
    Vaccine; 2016 Jul; 34(35):4205-4212. PubMed ID: 27354258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
    Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A
    Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later - an exploratory study.
    Gilca V; Sauvageau C; Panicker G; De Serres G; Ouakki M; Unger ER
    Hum Vaccin Immunother; 2019; 15(2):503-507. PubMed ID: 30252583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 9-Valent human papillomavirus vaccine: a review of the clinical development program.
    Luxembourg A; Moeller E
    Expert Rev Vaccines; 2017 Nov; 16(11):1119-1139. PubMed ID: 28956458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
    Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
    Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of the 9-valent HPV vaccine in men.
    Castellsagué X; Giuliano AR; Goldstone S; Guevara A; Mogensen O; Palefsky JM; Group T; Shields C; Liu K; Maansson R; Luxembourg A; Kaplan SS
    Vaccine; 2015 Nov; 33(48):6892-901. PubMed ID: 26144901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women.
    Ruiz-Sternberg ÁM; Moreira ED; Restrepo JA; Lazcano-Ponce E; Cabello R; Silva A; Andrade R; Revollo F; Uscanga S; Victoria A; Guevara AM; Luna J; Plata M; Dominguez CN; Fedrizzi E; Suarez E; Reina JC; Ellison MC; Moeller E; Ritter M; Shields C; Cashat M; Perez G; Luxembourg A
    Papillomavirus Res; 2018 Jun; 5():63-74. PubMed ID: 29269325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20-45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial.
    Shu Y; Yu Y; Ji Y; Zhang L; Li Y; Qin H; Huang Z; Ou Z; Huang M; Shen Q; Li Z; Hu M; Li C; Zhang G; Zhang J
    Vaccine; 2022 Nov; 40(48):6947-6955. PubMed ID: 36283897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
    Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
    J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV Vaccine.
    Klein NP; Wiesner A; Bautista O; Group T; Kanu K; Li ZL; McCauley J; Saxena K; Tota J; Luxembourg A; Bonawitz R
    Pediatrics; 2024 Aug; 154(2):. PubMed ID: 38978512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.
    Joura EA; Giuliano AR; Iversen OE; Bouchard C; Mao C; Mehlsen J; Moreira ED; Ngan Y; Petersen LK; Lazcano-Ponce E; Pitisuttithum P; Restrepo JA; Stuart G; Woelber L; Yang YC; Cuzick J; Garland SM; Huh W; Kjaer SK; Bautista OM; Chan IS; Chen J; Gesser R; Moeller E; Ritter M; Vuocolo S; Luxembourg A;
    N Engl J Med; 2015 Feb; 372(8):711-23. PubMed ID: 25693011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.